Navigation Links
Blood-vessel blocker aids cancer-killing virus
Date:11/27/2007

COLUMBUS, Ohio Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.

That immune response might be slowed, and the virus given more time to kill cancer cells, by blocking the growth of blood vessels in the tumor, new research here suggests.

The animal study indicates that pretreatment with an antiangiogenic agent a drug that blocks blood-vessel growth might improve the effectiveness of cancer-killing viruses.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center, is published online in the Journal of the National Cancer Institute with an accompanying editorial.

Our work suggest that antiangiogenic agents can reduce virus-induced inflammation in brain-tumor tissue and improve the antitumor efficacy of oncolytic virus therapy by lengthening the time it takes the immune system to clear the virus, says principal investigator Balveen Kaur, assistant professor of neurological surgery.

Much additional work is needed to validate these findings in other tumor models, but we hope that our findings will eventually be translated into clinical trials and one day help patients.

Kaur and her colleagues set out to learn how a cancer-killing, or oncolytic, virus affected the blood vessels in a brain-tumor model.

Kazuhiko Kurozumi, a visiting research scholar from Japan in Kaurs laboratory, first implanted rat glioma cells into the brains of several groups of rats. Seven days later, he injected a cancer-killing virus, called hrR3, into the growing tumors. This virus is a modified form of herpes simplex virus type 1 that reproduces and kills only tumor cells.

The virus caused the tumor blood vessels to become significantly more leaky compared with tumor blood vessels from control animals, and high numbers of white blood cells immune cells entered the tumor tissue.

The viru
'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Beta Blocker Doesnt Help Children With Heart Failure
2. How to design a cancer-killing virus
3. Virus Shows Some Cancer-Killing Abilities
4. Virus Could Help Drive Obesity
5. Scientists detect presence of marburg virus in african fruit bats
6. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
7. Human Papilloma Virus vaccines may decrease chances of oral cancer
8. New viruses to treat bacterial diseases -- My enemies enemy is my friend
9. FDA Approves New Roche West Nile Virus Blood Screening Test
10. Laser blasts viruses in blood
11. Bird Flu Virus Can Infect Fetus

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Nov. 27 Team Garmin-Slipstream, t...ted to ethical sporting and developing the next ge...t it will become Team Garmin-Transitions with the ...f the team. Transitions Optical is the world,s lea...e most advanced photochromic technology in the wid...
(Date:11/27/2009)...ngs has announced that it has become a national sp...est nonprofit organizations dedicated to arthritis... Delray Beach, FL (Vocus) November ... a company specializing in the marketing and retai...s announced today that is has become a national sp...
(Date:11/27/2009)...ical, economic burdens, study predicts , ...of people with diabetes in the United States is ex...dy predicts. , That would bring the total by 20...up from 23.7 million today. , , At the same time...riple, the study also warns, rising from an estima...
(Date:11/27/2009)...trade; announced today that Spectrum Health (Grand...rprise orthopedic templating solution and its Trau... (PRWEB) November 27, 2009 -- Voyant Healt...nd Rapids, Michigan) has licensed its TraumaCad En...aumaCad Extend workflow solution, to allow its ort...
(Date:11/27/2009)...ufacturers who use medical load cells at the heart...by bringing in technology partner Flintec early in...ive medical manufacturers are calling in Flintec l...jects, ensuring that progress will not be constrai...tdated technology. , (PRW...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...rmed at the evolution of causal organisms of hit...ey warn is the result of overzealous use of antibi...cement by the U.S Centers For Disease Control (CDC...creating worry lines on many a health expert. ...
...y predictor for liver cancer, says a US study. ...ne biomarker,// researchers at Columbia University... a means for early detection of liver cancer, says...have been associated with the development of liver...
...weight successfully should drink at least two litr...ction Centre in the German state of Rhineland-Pala...ht people drank too little and often mistook thirs...r metabolism and also improve skin tone. The...
...growing incidents of suicides and fratricides in t...ay called for steps to "urgently" address the// is...ases continues to be a cause of concern and must b...es in 2006. There have been 21 cases this year alo...
...ntries, those called up to risk their lives in the... and even ill-treated. Apparently the US is no exc...red out their grievances during a hearing of the P...th care system as a labyrinth, said their families...
...maceuticals Incorporated, a global biotechnology c...a trial on new hepatitis C drug, telaprevir. The d..., it has been shown. The planned interim resu...f the Liver (EASL). This drug has an enormous...
Other Medicine News:Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Antony Concerned Over Growing Suicide Rates in Armed Forces 2Health News:Military Healthcare Lacks Compassion, Say US Soldiers 2Health News:New Hepatitis C Drug Shows Promise 2
(Date:11/25/2009)..., , MOUNTAIN VIEW, Calif., Nov. 25 /PRNewsw... Phase II/III clinical data from the Company,s PRO...aluation in Crohn,s disease Trial) of Traficet-EN(... Crohn,s disease demonstrated clinical efficacy wi...he study demonstrated evidence of clinical efficac...
(Date:11/24/2009)..., , PITTSBURGH, Nov. 24 ... have been in coma for 23 years following an auto ...uring that time and was the subject of a Good Morn...red in the segment to illustrate how people with L...communication. ,, WHEN: Good Morning America -...
(Date:11/24/2009)..., , MADISON, N.J., Nov. 24 /PRNewswire-...: DGX ), the world,s leading provider of diagnos...hat it is scheduled to speak at the 21st Annual Pi.... The presentation is scheduled for Wednesday, De...ring the conference, the company will reaffirm its...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Bionovo Announces Pricing of Securities Offering 58766 1Bionovo Announces Pricing of Securities Offering 58766 2Bionovo Announces Pricing of Securities Offering 58766 3Yongye International Announces 2010 2012 Strategic Plan 14335 1Yongye International Announces 2010 2012 Strategic Plan 14335 2Yongye International Announces 2010 2012 Strategic Plan 14335 3Yongye International Announces 2010 2012 Strategic Plan 14335 4Yongye International Announces 2010 2012 Strategic Plan 14335 5Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 1Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 2
...T High-Risk Registry Data Shows Improved Symptomat...tients Treated with the MitraClip(R) System , , O...repair using the MitraClip(R) system in symptomati...al regurgitation (FMR) improves patient clinical s... 12-month data from the high-risk registry arm of ...
...RK, March 27 The Michael J. Fox Foundation announ... total to seven research teams working to improve ...nding was awarded under the Foundation,s Improvin...the Brain . The program is designed to address two...tive treatments for Parkinson,s disease: the need ...
Other Medicine Technology:MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up 2MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up 3Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease 2
Naked Gold 20 nm - 50 OD
...., PalmScan P2000] device is intended as a portabl...A-mode pulsed-echo ultrasound,technology, and th...hickness (CT) and,epithelium thickness (ET) of h...er,interfaces; a complete version and a simplifi...
...almScan A2000] device is intended as a portable,...de pulsed-echo ultrasound,technology, and thus m...(AL), anterior,chamber depth (ACD), and lens thi...evice is also intended for calculating the optical...
...low TLR (<1%) and stroke rate - demonstrating the ...durability., , , High Radial Strength: Easi...easing lumen diameter with chronic outward force.,...ortening, low profile design, Cordis TRUMARK™...
Medicine Products: